Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cancer. The usual approach is defined as the care most people get for non-small cell lung cancer.

Trial Details

NCT ID
NCT06686771
Phase
PHASE3
Sponsor
Canadian Cancer Trials Group
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • SBRT
  • First or second-line standard of care therapy
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Duarte, California, United States|34.13945,-117.97729
  • Irvine, California, United States|33.66946,-117.82311
  • Grand Junction, Colorado, United States|39.06387,-108.55065
  • Boise, Idaho, United States|43.6135,-116.20345

Key Eligibility Criteria

  • Metastatic disease (stage IV) detected on imaging and histologically and/or cytologically confirmed NSCLC as per the WHO Classification of Tumors a…
  • Oligoprogression on first-line ICI +/- chemotherapy systemic therapy after at least 3 cycles.
  • All sites of oligoprogression can be safely treated with SBRT or ablative radiotherapy as determined by radiation treatment preplan, including avai…
  • Patients with treated CNS disease who have radiologic and clinical evidence of stable brain metastases, with no evidence of cavitation or hemorrhag…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →